Source
California Poison Control System, Department of Clinical Pharmacy, University of California, San Francisco, CA 94143-1369, USA. susank@calpoison.org
Abstract
INTRODUCTION:
Little is known about behaviors linked to gamma hydroxybutyrate (GHB) morbidity.
METHODS:
We surveyed 131 GHB users, using logistic regression to test the associations between the high risk behaviors and hospital treatment for GHB (26 [20%] of subjects).
RESULTS:
Increased risk of GHB hospital treatment was associated with: co-ingestion of ethanol (OR 5.2; 95% CI 1.7-16), driving under the influence of GHB (OR 3.2; 95%, CI 1.3-7.8),use of GHB to treat withdrawal symptoms (OR 2.9; 95% CI 1.1-7.9), and co-ingestion of ketamine (OR 2.7; 95% CI 1.1-6.7).
CONCLUSION:
Targeted prevention activities could focus on selected high-risk behaviors.